Abstract
The article below furnishes information about the Nano Imaging Services business deal. The investment was made by a subsidiary of Merck & Co., Merck Capital Ventures or MCV. MCV invests in companies, which work towards the betterment of the pharmaceutical industry and other health related sectors. The amount invested was $1.5 million.
Reports reveal that there was an announcement of Nano Imaging Services business deal with Merck Capital Ventures on the 26th of February 2008. The amount raised from the Nano imaging services business deal was $1.5 million. Merck Capital Ventures, LLC invested this amount needed for the improvement as well as expansion of the services of the company (Nano Imaging Services).
The various services offered by Nano Imaging Services are as follows:
Visual inspection
- Experiments pertaining to antibody labeling
- Statistical characterization
- 3D reconstruction
- Nanometer scale
The company provides TEM or 3D transmission electron microscope related services to the companies manufacturing large "molecule bio pharmaceuticals". By the use of transmission electron microscope services related to imaging, the biopharmaceutical producers are able to view the various structures of macromolecules they create, the resolution being about a nanometer.
Reasons for carrying out the Nano Imaging Services business deal:
The capital raised from the Nano Imaging services business deal, is reckoned to be used for the betterment of the services of the company and also enhancement of the products offered by the company. In other words, the money raised from the business deal is likely to be used for revamping the entire company more so when the company (Nano Imaging Services) intends to shift its base from San Diego to California.
Profile of the investing company- Merck Capital Ventures or MCV:
Being a subsidiary of the company Merck & Co., Inc aims at financing the various activities of companies, which are indulging in emerging areas like delivery, commercialization as well as distribution of services related to health care as well as pharmaceuticals. The company enters into business deals only with those firms, engaged in the development of the pharmaceuticals and allied health care sectors.